Arena, Eisai Issues Update On Lorcaserin FDA Advisory Committee Meeting - Quick Facts

Arena Pharmaceuticals, Inc. (ARNA) and Eisai Inc. said that the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential risks, when used long-term in a population of overweight and obese individuals to allow marketing approval. Lorcaserin, which Arena discovered and has developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese or patients who are overweight and have at least one weight-related co-morbid condition.

The company noted that the FDA has assigned a PDUFA date, the target date for the agency to complete its review of the lorcaserin New Drug Application, of October 22, 2010.

For comments and feedback contact: editorial@rttnews.com

Follow RTT